BRPI0819138B8 - composição, e, cartucho, conjunto ou dispositivo dispensador - Google Patents

composição, e, cartucho, conjunto ou dispositivo dispensador

Info

Publication number
BRPI0819138B8
BRPI0819138B8 BRPI0819138A BRPI0819138A BRPI0819138B8 BR PI0819138 B8 BRPI0819138 B8 BR PI0819138B8 BR PI0819138 A BRPI0819138 A BR PI0819138A BR PI0819138 A BRPI0819138 A BR PI0819138A BR PI0819138 B8 BRPI0819138 B8 BR PI0819138B8
Authority
BR
Brazil
Prior art keywords
composition
per unit
unit dose
cartridge
dispensing device
Prior art date
Application number
BRPI0819138A
Other languages
English (en)
Inventor
Peke Meijer Erwin
Groenendijk Martine
Joseph Gerardus Hendrikus Kamphuis Patrick
Johan Joseph Hageman Robert
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39591591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0819138(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of BRPI0819138B1 publication Critical patent/BRPI0819138B1/pt
Publication of BRPI0819138B8 publication Critical patent/BRPI0819138B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

composição, cartucho, conjunto ou dispositivo dispensador, e, uso da composição. a invenção refere-se a uma composição compreendendo (i) uridina em forma de nucleobase, nucleotídeo e/ou nucleosídeo; (ii) ácido docosaexaenóico (dha) e/ou ácido eicosapentaenóico (epa); e (iii) um tocoferol e/ou um equivalente do mesmo, sendo que referida composição apresenta: a) um peso de 200 a 3000 mg por dose unitária; b) um teor de energia inferior a 50 kcal por dose unitária; e/ou c) um volume entre 0,1 e 10 ml por dose unitária. a invenção refere-se também ao uso de referida composição na redução da carga de placa abeta e neurodegeneração, no tratamento de doenças relacionadas com funcionamento deficiente dos nervos, em particular demência, mal de alzheimer e distúrbios da memória.
BRPI0819138A 2007-11-02 2008-10-27 composição, e, cartucho, conjunto ou dispositivo dispensador BRPI0819138B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL2007/050529 WO2009057994A1 (en) 2007-11-02 2007-11-02 Unit dosage for brain health
PCT/NL2008/050672 WO2009058005A2 (en) 2007-11-02 2008-10-27 Unit dosage for brain health

Publications (2)

Publication Number Publication Date
BRPI0819138B1 BRPI0819138B1 (pt) 2019-09-03
BRPI0819138B8 true BRPI0819138B8 (pt) 2021-05-25

Family

ID=39591591

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819138A BRPI0819138B8 (pt) 2007-11-02 2008-10-27 composição, e, cartucho, conjunto ou dispositivo dispensador

Country Status (9)

Country Link
US (1) US8283336B2 (pt)
EP (2) EP2214683B9 (pt)
CN (1) CN101842103A (pt)
BR (1) BRPI0819138B8 (pt)
DK (1) DK2214683T3 (pt)
ES (1) ES2430846T3 (pt)
PL (1) PL2214683T3 (pt)
PT (1) PT2214683E (pt)
WO (2) WO2009057994A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010000224A (es) 2007-06-26 2010-05-03 Nutricia Nv Mejoramiento de la memoria en individuos con mini-examen de estado mental de 24-26.
US20110086914A1 (en) * 2009-10-13 2011-04-14 Bailes Julian E Methods for Treating Traumatic Brain Injury
US20110257267A1 (en) * 2009-10-13 2011-10-20 Kevin Hadley Reducing the Risk of Pathological Effects of Traumatic Brain Injury
DE102011008016A1 (de) * 2011-01-06 2012-07-12 Johannes F. Coy Schokoladenmasse
WO2013066153A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Composition for improving neuropsychological test battery score
RU2014121888A (ru) * 2011-10-31 2015-12-10 Н.В. Нютрисиа Композиция для улучшения оценки батареи нейропсихологических тестов
WO2013066152A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
WO2013066151A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Improving recognition
AU2013226627B2 (en) * 2012-03-02 2017-05-25 N.V. Nutricia Method for improving functional synaptic connectivity
GB201205856D0 (en) * 2012-04-02 2012-05-16 Randall Jeremy A P Food supplement to support brain function
WO2014171813A1 (en) * 2013-04-17 2014-10-23 N.V. Nutricia Nutritional composition for improving brain function in phenylketonuria
US20190314442A1 (en) * 2016-02-22 2019-10-17 Newtricious B.V. Composition for the prevention or treatment of neurodegenerative diseases
WO2021019580A1 (en) * 2019-07-26 2021-02-04 Prosol S.P.A. Composition comprising 5'-ribonucleotides for use in the treatment of alzheimer's disease
WO2023041776A1 (en) 2021-09-17 2023-03-23 N.V. Nutricia Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2007350A6 (es) * 1987-05-29 1989-06-16 Ganadera Union Ind Agro Productos alimenticios enriquecidos con nucleosidos yno nucleotidos para la nutricion infantil y de adultos, y procedimiento para su preparacion.
AU769645B2 (en) 1987-05-29 2004-01-29 Abbott Laboratories Nourishing products enriched with nucleosides and/or nucleotides for infants and adults and processes for their preparation
ATE120930T1 (de) 1990-10-24 1995-04-15 Sandoz Nutrition Ltd Vollwertnahrung aus hydrolysierten löslichen faserstoffen.
ES2123903T5 (es) 1995-08-04 2011-02-22 N.V. Nutricia Composición nutritiva conteniendo fibra.
US5792501A (en) * 1996-04-15 1998-08-11 The Iams Company Queen's milk replacer
US5780081A (en) * 1996-10-28 1998-07-14 Nestec S.A. Fortification of food with calcium and process of making
US6288116B1 (en) * 1998-05-13 2001-09-11 Novartis Nutrition Ag Method of administration of a nutritional product to a person having renal failure
US6245379B1 (en) * 1998-09-30 2001-06-12 The Iams Company Method of administering a milk substitute to critical care animals
US6630452B2 (en) * 2000-02-17 2003-10-07 Wyeth Nutritional formulation containing prebiotic substances
US6420342B1 (en) * 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
DE10057976B4 (de) 2000-11-22 2005-02-03 Südzucker AG Mannheim/Ochsenfurt Verfahren zur Herstellung von Pektinhydrolyseprodukten
US6511696B2 (en) * 2000-12-13 2003-01-28 Novartis Nutrition Ag Infant formula with free amino acids and nucleotides
PT1390378E (pt) * 2001-04-30 2009-07-23 Trommsdorff Arzneimittel Ésteres de uridina farmaceuticamente activos
EP1634599A1 (en) * 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
WO2006031683A2 (en) 2004-09-15 2006-03-23 Massachusetts Institute Of Technology Compositions containing uridine, and methods utilizing same
BRPI0613303A8 (pt) * 2005-05-23 2018-01-30 Massachusetts Inst Technology composições que contêm pufa e/ou uridina e métodos de uso das mesmas
BRPI0613358A8 (pt) 2005-07-08 2017-12-26 Dsm Ip Assets Bv ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
US7829126B2 (en) * 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
DK1800675T3 (da) * 2005-12-23 2011-09-05 Nutricia Nv Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens
EP1803358A1 (en) * 2005-12-28 2007-07-04 Laboratorios Ordesa, S.L Infant immunological formula

Also Published As

Publication number Publication date
EP2214683A2 (en) 2010-08-11
PL2214683T3 (pl) 2013-12-31
WO2009057994A1 (en) 2009-05-07
CN101842103A (zh) 2010-09-22
DK2214683T3 (da) 2013-10-21
EP2214683B9 (en) 2013-12-25
ES2430846T3 (es) 2013-11-22
EP2537521A1 (en) 2012-12-26
WO2009058005A3 (en) 2009-07-16
BRPI0819138B1 (pt) 2019-09-03
US20100261669A1 (en) 2010-10-14
US8283336B2 (en) 2012-10-09
PT2214683E (pt) 2013-10-17
EP2214683B1 (en) 2013-07-10
WO2009058005A2 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
BRPI0819138B8 (pt) composição, e, cartucho, conjunto ou dispositivo dispensador
MA33044B1 (fr) Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient
FI2170104T4 (fi) Ravintokoostumus esioireisille dementiapotilaille
PE20081150A1 (es) Inhibidores de dipetidilpeptidasa
RU2010102237A (ru) Улучшение памяти у пациентов с оценкой 24-26 баллов по краткой шкале оценки психического статуса
JP2014532654A5 (pt)
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
EA202091999A2 (ru) Применение ингибиторов dpp iv
MX2009003305A (es) Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso.
CO6390078A2 (es) Inihibidores de syk de imidazopirazina
TN2011000209A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CL2008003582A1 (es) Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash).
PE20110711A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
BR112013031117A8 (pt) Scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos.
AR059864A1 (es) Compuesto de benzamida composicion farmaceutica que lo comprende su uso para preparar un medicamento y procedimientos para su preparacion
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
GT200800235A (es) Formulacion de medicamento liquida
AR049876A1 (es) Composiciones farmaceuticas para tratar enfermedades de la piel que comprenden una combinacion de epinastina y uno o mas minerales adicionales o uno o mas farmacos brutos
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators
UY30029A1 (es) Derivados de piperidina, sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2641 DE 17-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.